2026-10-25
CRA International, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 26,944 +1.18%
S&P 7,385 +0.42%
GOLD $4,067 −1.12%
BTC $75,586 −0.47%
VIX 25.28 −10.29%
latest tape · as of 18:01 UTC
The Screen · Industrials · Consulting Services
CRA International, Inc.
CRAI · Nasdaq · USD · Market cap $1.3B · 971 employees
CRA International, Inc., together with its subsidiaries, provides economic, financial, and management consulting services worldwide.
Not yet scored202.94 USD
Price as of 5 Nov 2026Daily close, not a live quote
Screened 2026-11-05 · the tape above runs as of 18:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price202.94 USD at the 5 Nov 2026 close
- Our value readFair vs our fair value, as of 5 Nov 2026
- Our regime readMarkup, as of 5 Nov 2026
- Ethical screenNot yet scored
- Last reviewed5 Nov 2026 (1 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
PRICE · ONE YEAR
Our fair-value range: $220.50 to $254.02, base estimate $220.88 (screen dated 2026-11-05).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical screen not yet scored
Price202.94 USD
Fair value220.88
Ethical score70.0/100
Value readFairas of 5 Nov 2026
Our investment reviews on this name
2026-10-29Read Markup200.14+1.4% to today ✓Accumulation gives way to Markup after a 13% rise in 7 days
2026-10-22Read Accumulation177.35+14.4% to today ✓Markup gives way to Accumulation with volume flow in agreement
2026-10-11Read Markup171.43+18.4% to today ✓Markdown gives way to Markup after a 6% rise in 9 days
2026-10-02Read Markdown161.97+25.3% to today Markup gives way to Markdown after a 5% slide in 5 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its markup label.
CRA International, Inc. holds its Markup at $202.94. The statistical read favours the sellers, held for 6 days.
| Phase | Markup |
| Quantitative state | The statistical read favours the sellers, held for 6 days |
| Price at the screen | $202.94 |
| Valuation | 27.06 trailing · 21.22 forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | 0.61 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 20.23% | Below 33% | Interest-bearing debt is just 20.2% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 32.04% | Below 49% | Money owed to the company is 32.0% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
CRA International, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
CRA International, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 20%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Our analysis reads Fair vs our fair value, as of 5 Nov 2026: it trades at roughly an 8% discount to our $220.88 fair value, 12.80% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 8.1% discount to the base estimate.
Third-party analyst targets: 2 covering, consensus Buy. The average target sits +23% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $220.88, with a range of $220.50 to $254.02, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhen lawsuits need number crunchers this firm delivers
Picture a corporate legal team facing a billion dollar antitrust case. They need someone to model damages and regulatory fallout without the drama of a courtroom. CRA International supplies exactly that expertise, advising on litigation and financial puzzles across borders with a decade of steady 10% revenue growth behind it.
The business earns a solid 23% return on equity and clears a 6% profit margin at a forward multiple of 17.8 times earnings. Our fair value sits 30% above the current price and the ethical screen raises no flags, yet the opportunity rating stays at none because the moat remains unclear and only two analysts follow the name.
Cyclical swings in case volumes and client spending can compress margins quickly even when the multiple looks reasonable today. Currency moves and competition from larger advisory networks add further pressure that the numbers alone do not capture.
Analysis, not advice.
| Forward P/E | 21.2xpriced for continued growth |
| Trailing P/E | 27.1xa premium valuation |
| EPS, trailing | 7.50 |
| EPS, forward | 9.56 |
| Revenue growth | +12.8%steady growth |
| Profit margin | 6.2%thin but positive margins |
| Return on equity | 26.0%an exceptional return on shareholder capital |
| FCF yield | 2.47% |
| Dividend yield | 152.00% |
| Debt to equity | 1.67a meaningful debt load worth watching |
| Current ratio | 0.82below 1: short-term bills exceed liquid assets |
| Beta | 0.61steadier than the market |
| Short interest, float | 0.05% |
| 52-week range | 132.17 - 227.29 |
| Market cap | $1.3B |
| Employees | 971 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeCRAI trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-11-05
Markup $194.75
-0.3% Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.3% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (2 analysts) rates it none, with a mean price target of $252. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04
Markup $195.26
-0.4% Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.4% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (2 analysts) rates it none, with a mean price target of $252. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03
Markup $196.08
+0.0% Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (2 analysts) rates it none, with a mean price target of $252. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02
Markup $196.08
+0.0% Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (2 analysts) rates it none, with a mean price target of $252. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01
Markup $196.08
-0.4% Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.4% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (2 analysts) rates it none, with a mean price target of $252. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31
Markup $196.77
+0.0% Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (2 analysts) rates it none, with a mean price target of $252. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30
Markup $196.77
-1.7% Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 1.7% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (2 analysts) rates it none, with a mean price target of $252. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29
Markup · changed $200.14
+12.9% Entry 9
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 12.9% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (2 analysts) rates it none, with a mean price target of $252. Since the last review it its composite score eased. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22
Accumulation · changed $177.35
+3.5% Entry 8
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.5% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (2 analysts) rates it none, with a mean price target of $252.
2026-10-11
Markup · changed $171.43
+5.8% Entry 7
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (2 analysts) rates it none, with a mean price target of $252.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Exponent (EXPO) Tops Q3 Earnings and Revenue Estimates Yahoo Finance · 8d ago
- CRA International (CRAI) Stock Trades At A Premium After Raised Guidance Yahoo Finance · 12d ago
- Booz Allen Hamilton (BAH) Q2 Earnings Beat Estimates Yahoo Finance · 14d ago
- Charles River Associates (CRA) to Host Third-Quarter Fiscal 2026 Financial Results Conference Call on November 5 Yahoo Finance · 15d ago
- Charles River Associates (CRA) Bolsters Life Sciences Practice with Appointment of Christopher Zealey as Vice President Yahoo Finance · 6 Oct 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
ICFIICF International, Inc.
ROMARoma Green Finance Ltd
HURNHuron Consulting Group Inc.
FCNFTI Consulting, Inc.
SBCSBC Medical Group Holdings Inc
PPHCPublic Policy Holding Company Inc
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $145.84 | +1.7% | $0.57 | $1,021 | +2.1% |
| 2 months | $159.60 | -7.1% | $0.57 | $933 | -6.7% |
| 3 months | $162.90 | -9.0% | $0.57 | $914 | -8.6% |
| 6 months | $199.59 | -25.7% | $1.14 | $749 | -25.1% |
| 1 year | $183.80 | -19.3% | $2.20 | $819 | -18.1% |
| 2 years | $170.03 | -12.8% | $4.09 | $896 | -10.4% |
| 3 years | $95.57 | +55.2% | $5.71 | $1,611 | +61.1% |
| 5 years | $78.82 | +88.1% | $8.29 | $1,986 | +98.6% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever CRAI does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.